The availability of drugs for stable COPD treatment in China: a cross-sectional survey

Introduction

Chronic obstructive pulmonary disease (COPD) is currently one of the leading causes of death worldwide1,2. The total prevalence of COPD in China was 8.6% (95% CI 7.5–9.9)3, and the global prevalence of COPD among people aged 30–79 years was 10.3% (95% CI 8.2,12.8)4,5. COPD causes approximately three million deaths annually, 90% of which occur in low- and middle-income countries (LMICs)6. COPD also imposes a significant macroeconomic burden that is unevenly distributed among different geographical locations and socioeconomic levels7. However, a significant missed opportunity of COPD treatment has been reported in LMICs, highlighting the need to understand and improve the current conditions of COPD management8,9.

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2023 and Chinese Guidelines for the Diagnosis and Management of COPD (revised version 2021), management approaches of COPD include pharmacological treatments, smoking cessation, vaccination, pulmonary rehabilitation and education of patients10,11. Among these approaches, pharmacological treatments were regarded as the cornerstone of COPD management, as these drugs are beneficial for reducing lung function decline and mortality rates11. However, the availability of drugs for COPD varies across different geographical locations12,13,14. In 36 countries studied across WHO regions, the average availability of generic salbutamol inhalers was 29% in the public sector and 61% in the private sector15. In Southeast Asia, the public sector had the lowest mean availability at 5%15. Another recent systematic review showed that the availability of inhaled corticosteroid–long-acting β-agonist (ICS-LABA) was lower than 80% in four countries16. All these studies suggested that the availability of drugs for patients with COPD was still a challenge to address.

Furthermore, the Chinese population has been suffering from inaccessible and unaffordable health care for decades17. In Zhejiang Province, one of the top five provinces in China in terms of economic development, the availability of 50 essential medicines is low in the public and private sectors, and the availability of salbutamol inhalers in public and private pharmacies is 70% and 40%, respectively18. However, there is still limited evidence on drug availability for stable COPD treatment in China. This survey aimed to investigate the availability of both inhaled and oral drugs for stable COPD treatment across Chinese hospitals with different characteristics, which may provide another perspective over the current challenges and potential solutions in stable COPD management.

Methods

Drug list for COPD patients

Drug selection of this survey was conducted based on the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (revised version 2021)10. Twenty-three kinds of drugs, ranging from inhalation drugs (monotherapy, double therapy and triple therapy) to oral drugs (expectorants, theophylline, antibiotics and bacterial lysates), were included in this survey (Table 1).

Table 1 A list of essential medicines for COPD treatment according to China COPD guidelines8.
Full size table

Survey design and data collection

A questionnaire was used to conduct this cross-sectional survey from March 2023 to December 2023. The questionnaire was composed of three parts: (1) Baseline information of the hospital, including level (primary/secondary/tertiary/temporarily uncertain), public or private status, establishment of an independent respiratory department (yes/no), number of beds and doctors in the respiratory department, and establishment of a respiratory outpatient (yes/no). (2) Availability of different kinds of inhalation drugs (yes/no). (3) Availability of different kinds of oral drugs (yes/no). Doctors who worked in different hospitals in China completed the survey via WeChat19. The website Wenjuanxing (https://www.wjx.cn/) was used for data collection. Invalid responses were defined as follows and excluded from further analysis: (1) Duplicate responses providing drug availability data of the same hospital. If two or more responses from the same hospital were received, we contacted this hospital for the most accurate response and removed the others. (2) Incomplete answers to questions. (3) Responses from specialized hospitals which are not responsible for COPD management, such as children’s hospitals and psychiatric hospitals.

Statistical analysis

Availability of all categories and all kinds of drugs was analyzed. The drug categories included short-acting β2 agonist (SABA), long-acting β2 agonist (LABA), short-acting antimuscarinics (SAMA), long-acting antimuscarinics (LAMA), LAMA/LABA, ICS/LABA, and ICS/LAMA/LABA, expectorants, theophylline, antibiotics and bacterial lysates (Table 1). Availability of drug category was defined as having at least one kind of drug within each category (e.g., Hospitals having either terbutaline or salbutamol were regarded as SABA available). Availability of each kind of drug was defined as having the particular kind of drugs (e.g., Hospitals having terbutaline were regarded as terbutaline available). Subgroup analyses were then conducted to determine the availability of drugs in hospitals with different characteristics. Categorical variables are presented as numbers (percentages) and were analyzed using the chi-square test. All the data were analyzed and presented using SPSS 26.0 (IBM Corporation) and GraphPad Prism 8.0.

Results

Baseline characteristics of hospitals

A total of 1425 responses to the questionnaire were ultimately returned, and 1018 hospitals (94.99% are public hospitals) from 31 provinces were enrolled after excluding invalid responses. The geographic distribution of the enrolled hospitals was presented in supplementary materials (Table S1). For baseline information, primary, secondary and tertiary hospitals comprised 31.93%, 22.89% and 42.14%, respectively. A total of 547 (53.73%) hospitals established independent respiratory departments, most of which also established respiratory outpatient departments (96.89%). Among them, respiratory departments with 50–80 beds (41.13%) or 1–10 doctors (44.06%) accounted for the largest proportion (Fig. 1).

Fig. 1: Baseline characteristics of all enrolled hospitals in this survey.
figure 1

A Level of hospitals (n = 1018). B Public or private hospitals (n = 1018). C Establishment of independent respiratory department (n = 1018). D Number of beds in the respiratory department (n = 547). E Number of doctors in the respiratory department (n = 547). F Establishment of respiratory outpatient (n = 547).

Full size image

Overall availability of drugs for COPD treatment

The overall availability of all categories of drugs were presented in Fig. 2, suggesting insufficient supply of all COPD-related drugs, with only short-acting β2 agonists (80.6%), expectorants (88.2%) and antibiotics (84.3%) reaching 80%. The overall availability of each kind of drug was summarized in Fig. 3. Salbutamol (78.0%), glycopyrrolate/formoterol (G/F) (26.5%), budesonide/formoterol (Bu/F) (63.1%), budesonide/glycopyrronium/formoterol (B/G/F) (42.9%) and azithromycin (84.3%) reached the highest percentages among the monotherapies, LAMA/LABA, ICS/LABA, ICS/LAMA/LABA and oral drugs, respectively. The availability of all kinds of drugs in different levels of hospitals was presented in Fig. 4, which showed that the availability of all kinds of drugs in primary hospitals was significantly poorer than that in secondary and tertiary hospitals (all p < 0.001). Although inhaled drugs play essential roles in management of COPD patients, most inhaled drugs did not reach an availability of 20% in primary hospitals, except for salbutamol (59.7%), tiotropium bromide (20.0%) and beclometasone/formoterol (23.1%).

Fig. 2: Availability of all categories of drugs.
figure 2

SABA Short-acting β2 agonist, LABA Long-acting β2 agonist, SAMA Short-acting antimuscarinics, LAMA long-acting antimuscarinics, ICS Inhaled corticosteroids.

Full size image
Fig. 3: The overall availability of all kinds of drugs (n = 1018).
figure 3

A Monotherapy; B LAMA/LABA; C ICS/LABA; D ICS/LAMA/LABA; E oral drugs. SABA short-acting β2 agonist, LABA long-acting β2 agonist, SAMA short-acting antimuscarinics, LAMA long-acting antimuscarinics, ICS inhaled corticosteroids.

Full size image
Fig. 4: Availability of all kinds of drugs in different levels of hospitals.
figure 4

***p < 0.001. A Monotherapy; B LAMA/LABA; C ICS/LABA; D ICS/LAMA/LABA; E oral drugs. SABA short-acting β2 agonist, LABA long-acting β2 agonist, SAMA short-acting antimuscarinics, LAMA long-acting antimuscarinics, ICS inhaled corticosteroid.

Full size image

Subgroup analyses

Results of a more detailed subgroup analyses for drug availability in hospitals with different characteristics were presented in Tables 2–3. The availability of all categories of drugs differed significantly among different hospital levels (primary/secondary/tertiary/temporarily uncertain) (all p < 0.001) and the establishment of a respiratory department (yes/no) (all p < 0.001). However, few differences in drug availability were observed between public hospitals and private hospitals, except for SAMA (p = 0.032). Furthermore, for hospitals with an independent respiratory department, the availability of most drugs differed among departments with different numbers of beds, except for SABA (p = 0.181), theophylline (p = 0.133) and antibiotics (p = 0.061) (Table 3). The availability of most categories of drugs was also different among departments with different numbers of doctors, except for SABA (p = 0.369), ICS/LABA (p = 0.140), expectorants (p = 0.350), theophylline (p = 0.138) and antibiotics (p = 0.337).

Table 2 Subgroup analysis over availability of drug categories among all hospitals (n = 1018).
Full size table
Table 3 Subgroup analysis over availability of drug category among hospitals with respiratory department (n = 547).
Full size table

Discussion

Drug availability serves as the cornerstone of chronic disease management. This cross-sectional survey investigated the availability of drugs for COPD treatment from 1018 Chinese hospitals with valid responses. Results of this survey suggested that the availability of drugs recommended for COPD treatment is still insufficient, and a significant availability gap still exists among hospitals at different levels. This survey also suggested that drug availability can be associated with multiple factors, including the establishment of respiratory departments, the number of beds in respiratory departments, and the number of doctors in respiratory departments.

Current evidence suggests an unmet therapeutic opportunity for COPD patients in LMICs, highlighting the importance of drug availability and sustainability in COPD management8,9. Zeng et al. noted that more than 30% of COPD patients were following inappropriate pharmacological therapies in a multicenter study20. Yang et al. reported that more than 10% of COPD patients with a high risk of exacerbation (GOLD group E) never received any long-acting inhaled drugs21. One potential cause for the above conditions may be attributed to insufficient essential drug supply16. Previous studies have reported the availability of COPD essential drugs in multiple LMICs around the globe. Stolbrink et al. noted that only 6 of 58 LMICs reached a SABA availability of 80%16. Plum et al. reported an ICS/LABA availability of 37.8% in 13 African countries22. Ozoh et al. also demonstrated the limited availability and affordability of COPD essential medicine in Nigeria23. Consistent with previous findings, results of the survey showed that there is lack of adherence to the National and Global COPD guidelines in the stable COPD management practice in China.

Furthermore, the significant gap of basic medical services among primary, secondary and tertiary hospitals cannot be ignored24. Previous studies have shown that patients treated at different hospital levels were associated with different levels of health education, healthcare quality and mortality rates24,25. Mao et al. reported that COPD patients in primary and secondary hospitals were characterized by a lower rate of pulmonary function examination and poorer use of inhaled drugs than those treated in teaching hospitals26. Results of this survey showed that drug availability for COPD patients was also significantly different among hospitals at different levels, and none of the drugs reached an availability of 80% in primary hospitals. These findings are consistent with previous studies, as insufficient and uneven essential drug supply for other chronic diseases like hypertension and dyslipidemia have already been reported27,28. One potential reason for the availability difference between primary hospitals and secondary/tertiary hospitals may be insufficient funding of primary care settings, which warrants further investigations.

The potential methods for improving the poor availability of COPD-related drugs to improve the quality of COPD management are summarized in Fig. 5, calling for stronger collaboration among multiple aspects29. The government, who are responsible for administration and supervision, needs to promote essential medicine programs. The government may also increase investments in primary hospitals to improve their healthcare quality and drug availability, as a large proportion of patients with COPD may seek for treatment in primary care settings30. Pharmaceutical companies may improve their competitiveness by placing emphasis on the management, investigation and production of drugs. Academic organizations may focus on developing and renewing treatment guidelines for COPD, which is beneficial for renewing essential medicine lists and improving the overall quality of COPD management. The benign competition within the market should also be encouraged to maintain drug quality and stimulate innovations. With the improvement of drug availability via the above methods, primary hospitals may provide sufficient medications and health education to patients with COPD. Primary hospitals may also receive assistance and guidance from more advanced hospitals in the management of stable COPD. Secondary and tertiary hospitals receive feedback from primary hospitals and provide further medical assistance to patients in need. Medical insurance departments may provide funding to all levels of hospitals and reduce the medical expenditure of COPD patients.

Fig. 5: Drug availability is the cornerstone of COPD management, which warrants efforts from multiple aspects.
figure 5

Created by figdraw.

Full size image

This survey also has some limitations. (1) Although this survey was conducted based on hospitals from 31 provinces, considerable variation has been revealed in the number of hospitals from different provinces in China, which may make the results less representative and cause potential bias. (2) In this survey, tertiary hospitals comprised 42.14% of the total sample; whereas in reality, the proportion of tertiary hospitals in China was less than 15% (Data source: The State Council of the People’s Republic of China). Although we conducted subgroup analyses to investigate drug availability in hospitals with different levels, this may still introduce potential bias to our results. (3) The guidelines for COPD are updated rapidly, and China has released a new primary care guideline in 202431, leading to updated medication information as well. Future studies may follow the newest guideline to update our results.

Taken together, our results found that the availability of drugs for stable COPD treatment is still an ongoing challenge for healthcare institutions in China. Insufficient supply of inhaled drugs and imbalanced drug availability among different levels of hospitals are major barriers that warrant further improvements.

Related Articles

Aerospace medicine in China: advancements and perspectives

With the rapid growth of China’s space industry, long-term manned space missions face challenges from the complex space environment, posing risks to human health. Aerospace medicine, a key field, addresses these risks by researching the impacts of space on biochemical changes, cognitive abilities, and immune systems. This article reviews China’s aerospace medicine research, summarizing efforts from various institutions and offering insights for future developments in the field.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Emerging insights in senescence: pathways from preclinical models to therapeutic innovations

Senescence is a crucial hallmark of ageing and a significant contributor to the pathology of age-related disorders. As committee members of the young International Cell Senescence Association (yICSA), we aim to synthesise recent advancements in the identification, characterisation, and therapeutic targeting of senescence for clinical translation. We explore novel molecular techniques that have enhanced our understanding of senescent cell heterogeneity and their roles in tissue regeneration and pathology. Additionally, we delve into in vivo models of senescence, both non-mammalian and mammalian, to highlight tools available for advancing the contextual understanding of in vivo senescence. Furthermore, we discuss innovative diagnostic tools and senotherapeutic approaches, emphasising their potential for clinical application. Future directions of senescence research are explored, underscoring the need for precise, context-specific senescence classification and the integration of advanced technologies such as machine learning, long-read sequencing, and multifunctional senoprobes and senolytics. The dual role of senescence in promoting tissue homoeostasis and contributing to chronic diseases highlights the complexity of targeting these cells for improved clinical outcomes.

A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation

Acute exacerbations of COPD (ECOPD) are an important event in the life of a COPD patient as it causes significant deterioration of physical, mental, and social health, hastens disease progression, increases the risk of dying and causes a huge economic loss. Preventing ECOPD is therefore one of the most important goals in the management of COPD. Before the patient is discharged after hospitalization for ECOPD, it is crucial to offer an evidence-based care bundle protocol that will help minimize the future risk of readmissions and death. To develop the content of this quality care bundle, an Expert Working Group was formed, which performed a systematic review of literature, brainstormed, and debated on key clinical issues before arriving at a consensus strategy that could help physicians achieve this goal. A 7-point consensus strategy was prepared, which included: (1) enhancing awareness and seriousness of ECOPD, (2) identifying patients at risk for future exacerbations, (3) optimizing pharmacologic treatment of COPD, (4) identifying and treating comorbidities, (5) preventing bacterial and viral infections, (6) pulmonary rehabilitation, and (7) palliative care. Physicians may find this 7-point care bundle useful to minimize the risk of future exacerbations and reduce morbidity and mortality.

Responses

Your email address will not be published. Required fields are marked *